Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Atsuyuki Tomizawa"'
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 5, Iss 4 (2016)
BackgroundThe efficacy of P2Y12 inhibition for the prevention of cardiovascular events in patients with peripheral arterial disease (PAD) has been established. However, the therapeutic effects on ischemic limb complications are less clear. Accordingl
Externí odkaz:
https://doaj.org/article/07ba9bcbbc5846b59be784638a481f1f
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0154661 (2016)
Platelets play pivotal roles in both hemostasis and thrombosis. Although models of intravital platelet imaging are available for thrombosis studies in mice, few are available for rat studies. The present effort aimed to generate fluorescent platelets
Externí odkaz:
https://doaj.org/article/31ef4768d63f40569af20bd652e91259
Publikováno v:
European Journal of Pharmacology. 788:132-139
Previously, we showed preventive effects of prasugrel, a P2Y12 antagonist, in a non-human primate model of thrombotic middle cerebral artery occlusion (MCAO); however, it remains unclear if P2Y12 inhibition after MCAO reduces cerebral injury and dysf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcb1c83d9f1712d2b39bb7dd15a49165
https://doi.org/10.1016/j.ejphar.2016.06.023
https://doi.org/10.1016/j.ejphar.2016.06.023
Autor:
Kousaku Ohno, Atsuhiro Sugidachi, Yuka Morikawa, Yusuke Ito, Atsuyuki Tomizawa, Makoto Mizuno
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-11 (2018)
Scientific Reports
Scientific Reports
Vasodilator-stimulated phosphoprotein (VASP) is a member of actin regulatory proteins implicated in platelet adhesion. In addition, phosphorylation of VASP is utilised for the assessment of platelet reactivity in patients treated with P2Y12 receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bbd1a783a646fbd8f2154da750fedff
https://doi.org/10.1038/s41598-018-28181-8
https://doi.org/10.1038/s41598-018-28181-8
Publikováno v:
Thrombosis Research. 136:1245-1251
The present study examined the effects of prasugrel in a mouse model of thrombosis-induced neointimal hyperplasia. Following carotid artery injury by application of ferric chloride solution, thrombus formation was assessed on Day 1 and neointimal thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d91676b66260c1f25cda9ff846fffa1
https://doi.org/10.1016/j.thromres.2015.10.010
https://doi.org/10.1016/j.thromres.2015.10.010
Autor:
Yusuke Ito, Kousaku Ohno, Atsuhiro Sugidachi, Makoto Mizuno, Joseph A. Jakubowski, Atsuyuki Tomizawa
Publikováno v:
TH Open, Vol 01, Iss 02, Pp e92-e100 (2017)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Patients with acute coronary syndrome with diabetes mellitus (DM) exhibit an impaired platelet inhibitory response to clopidogrel which is only partially understood. DM was induced by the administration of streptozotocin (STZ) to 9-week-old mice. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::743d316e01f798446e011dd63f174aa0
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1605361
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0037-1605361
Publikováno v:
Thrombosis and Haemostasis. 110:769-776
SummaryPrasugrel is the third generation thienopyridine prodrug, and ticagrelor is a non-competitive direct acting P2Y12 antagonist. In phase 3 studies, both agents reduced ischaemic event rates compared to clopidogrel. The present in vitro human and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a75e027c7a9259269d43080e74a60ed
https://doi.org/10.1160/th13-03-0260
https://doi.org/10.1160/th13-03-0260
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 36
Background: The efficacy of P2Y 12 inhibition for the prevention of cardiovascular events in patients with peripheral arterial disease (PAD) has been established. However the therapeutic effects on ischaemic limb manifestations are less clear. Accord
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3133bea9575d1351ba9b55d2c48c92e
https://doi.org/10.1161/atvb.36.suppl_1.321
https://doi.org/10.1161/atvb.36.suppl_1.321
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The efficacy of P2Y 12 inhibition for the prevention of cardiovascular events in patients with peripheral arterial disease ( PAD ) has been established. However, the therapeutic effects on ischemic limb complications are less clear. Accord
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde835ef4aa21f9acce144d5138a891c
https://doi.org/10.1161/jaha.115.002889
https://doi.org/10.1161/jaha.115.002889
Publikováno v:
Stroke. 47
Introduction: Several clinical trials have demonstrated the benefits of thienopyridine monotherapy in ischemic stroke patients. Non-human primate models of ischemic stroke have been used for various antithrombotic agents; however, to our knowledge, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc0a09601b5ebd34388b035d6dca520d
https://doi.org/10.1161/str.47.suppl_1.wp278
https://doi.org/10.1161/str.47.suppl_1.wp278